BTIG initiated coverage of Connect Biopharma (CNTB) with a Buy rating and $10 price target The firm believes rademikibart is “set up to thrive” in the acute settings of both indications of asthma and chronic obstructive pulmonary disorder, supported by its unusually fast and best-in-class onset of effect, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Buy Rating for Connect Biopharma: Promising Clinical Data and Market Potential for Rademikibart
- Connect Biopharma presents data on rademikibart at ERS Congress
- Connect Biopharma Executives Increase Share Holdings
- Connect Biopharma management to meet virtually with Northland
- Connect Biopharma completes termination of ADR program, lists on Nasdaq